FDA approves Natpara for Hypoparathyroidism-NPS Pharma/Shire
The FDA has approved Natpara (parathyroid hormone), from NPS Pharma/Shire, as an adjunct to calcium and vitamin D to control hypocalcaemia in patients with hypoparathyroidism. NPS has previously indicated that this product is expected to be available in the second quarter of 2015.
In clinical studies, Natpara has been shown to increase serum calcium levels while reducing the need for oral calcium and active vitamin D and, in some cases, eliminate the need for active vitamin D altogether. The most common adverse reactions associated with Natpara and occurring in greater than 10% of individuals were: paresthaesia, hypocalcaemia, headache, hypercalcaemia, nausea, and hypoesthaesia, diarrhea, vomiting, arthralgia, hypercalciuria and pain in extremities.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
4 mins